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Introduction
During angiogenesis, nascent blood vessels initially form as 
endothelial  tubes  that  become  coated  with  pericytes.  Peri-
cytes are mobilized from preexisting vessels by the combined 
activities of several proliferation- and migration-stimulating 
factors,  including  matrix  metalloprotease  9  (MMP9)  and 
PDGF-BB. Mobilized pericytes migrate to the newly formed 
endothelial tube and, upon contact, induce vessel maturation 
and stabilization (von Tell et al., 2006). This process is re-
quired for normal angiogenesis, as lack of adequate pericyte 
coverage results in vessel abnormalities, including leakiness 
and  hemorrhaging  (Lindahl  et  al.,  1997;  Hellström  et  al., 
2001). Unlike normal vasculature, vessels within tumors are 
typically leaky, tortuous, and exhibit abnormal pericyte cov-
erage (Helmlinger et al., 1997; Benjamin et al., 1999; Eberhard 
et al., 2000). Antiangiogenic tumor therapy is believed to be 
effective at treating some types of cancer by selectively ab-
lating blood vessels that lack pericyte coverage, thereby in-
creasing the efficiency of blood transport within the tumor, 
which increases the delivery of chemotherapeutics (Gerhardt 
and Semb, 2008). Targeting pericyte recruitment was shown 
to increase the efficacy of antiangiogenic tumor therapy in a 
mouse model of islet carcinoma (Bergers et al., 2003), demon-
strating that modulation of pericyte behavior can be therapeu-
tically beneficial. Further development of such approaches, 
however, requires a better understanding of the biological fac-
tors that control pericyte behavior.
Secreted protein acidic and rich in cysteine (SPARC) is a 
matricellular  protein  whose  expression  is  induced  during   
angiogenesis (Lane et al., 1994; Iruela-Arispe et al., 1995). 
SPARC has been implicated in cellular processes critical to   
angiogenesis, including migration, proliferation, and differen-
tiation (Kupprion et al., 1998; Francki et al., 2003; Motamed   
et al., 2003; Chlenski et al., 2007). The activity of SPARC ap-
pears to be indirect and relies in part on its ability to influence 
various growth factor signaling pathways. For example, SPARC 
can directly interact with VEGF-A and with PDGF-BB and 
PDGF-AB and prevent their interaction with cell surface recep-
tors (Raines et al., 1992; Kupprion et al., 1998). However, SPARC 
P
ericytes  migrate  to  nascent  vessels  and  promote 
vessel stability. Recently, we reported that secreted 
protein acidic and rich in cysteine (SPARC)–deficient 
mice exhibited decreased pericyte-associated vessels in 
an  orthotopic  model  of  pancreatic  cancer,  suggesting 
that SPARC influences pericyte behavior. In this paper, 
we  report  that  SPARC  promotes  pericyte  migration  by 
regulating  the  function  of  endoglin,  a  TGF-1  acces-
sory receptor. Primary SPARC-deficient pericytes exhib-
ited  increased  basal  TGF-1  activity  and  decreased 
cell migration, an effect blocked by inhibiting TGF-1.   
Furthermore, TGF-–mediated inhibition of pericyte migra-
tion was dependent on endoglin and V integrin. SPARC 
interacted directly with endoglin and reduced endoglin 
interaction with V integrin. SPARC deficiency resulted in   
endoglin-mediated blockade of pericyte migration, aber-
rant association of endoglin in focal complexes, an increase 
in V integrins present in endoglin immunoprecipitates, and 
enhanced V integrin–mediated activation of TGF-. These 
results demonstrate that SPARC promotes pericyte migra-
tion by diminishing TGF- activity and identify a novel 
function for endoglin in controlling pericyte behavior.
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Results
SPARC deficiency results in defective 
pericyte recruitment in vivo and impaired 
pericyte migration in vitro
Previously, we found that orthotopic pancreatic tumors grown 
in SPARC
/ mice contained fewer  smooth muscle actin
+  
(-SMA
+) cell–invested blood vessels than tumors grown in 
SPARC
+/+ mice (Puolakkainen et al., 2004; Arnold et al., 2010). 
As -SMA is expressed by only a subset of pericytes, we sought 
to confirm this finding using the more general pericyte marker 
NG2 (Crisan et al., 2008). NG2 is expressed by resident peri-
cytes associated with MECA32
+ endothelial cells of the normal 
adult pancreas (Fig. 1 A). NG2
+ cells were found to express 
SPARC in the vasculature of the normal adult pancreas and 
PDAC (Fig. 1, B and C, respectively). We crossed P48Cre:
LSLKras
G12D:INK4A
lox/lox mice, which develop PDAC (Aguirre 
et al., 2003), to SPARC
+/+ and SPARC
/ mice. Comparison of 
NG2
+ cell recruitment between SPARC
+/+ PDAC and SPARC
/ 
PDAC mice revealed fewer pericyte-associated MECA32
+ ves-
sels in SPARC
/ PDAC tumors, confirming previous results 
(Fig. 1 F). We next asked whether endogenous SPARC influ-
enced the behavior of primary pericytes in vitro. We used anti-
NG2 immunomagnetic bead separation to purify pericytes from 
SPARC
+/+  and  SPARC
/  pancreas  digests.  Purified  primary 
cells expressed pericyte markers and induced bEnd.3 endothe-
lial cell cord formation (Fig. 1 G). Analysis of bEnd.3 cord param-
eters revealed that SPARC
/ pericytes induced fewer cords; 
however, these cords were on average wider than SPARC
+/+ 
pericyte-induced cords. To investigate the disparity in pericyte 
function further, we assessed focal adhesion formation in pri-
mary SPARC
+/+ and SPARC
/ pericytes (Fig. S1). We found 
that SPARC
+/+ pericytes exhibited more filopodia per cell com-
pared with SPARC
/ pericytes when spreading on fibronectin. 
Focal adhesion area was also greater in SPARC
/ pericytes, 
whereas the overall number was decreased.
We next assayed migration toward fibronectin, a provi-
sional matrix protein, using a transwell assay. SPARC
/ peri-
cytes exhibited a significantly reduced capacity to migrate, a 
feature that was reversed by the addition of recombinant SPARC 
(Fig. 2 A). Recombinant SPARC did not enhance the migration 
of SPARC
+/+ pericytes, suggesting that endogenous SPARC is 
sufficient for optimal migration (Fig. 2 C). Furthermore, small 
hairpin RNA (shRNA)–mediated knockdown or IgG-mediated 
neutralization of SPARC in SPARC
+/+ pericytes reduced their 
capacity to migrate (Fig. 2 B). Thus, pericyte-derived SPARC 
mediates pericyte recruitment to blood vessels, at least in part, 
by promoting cell migration.
Endogenous TGF-1 blocks migration of 
SPARC-deficient pericytes
SPARC can regulate TGF-1 activity in other cell types; there-
fore, we assessed the contribution of TGF-1 to the migration 
phenotype  of  SPARC
/  pericytes  (Schiemann  et  al.,  2003; 
Francki et al., 2004; Chlenski et al., 2007). For this, we used pri-
mary pericytes and the 10T1/2 mesenchymal cell line (Reznikoff 
et al., 1973). Like pericytes, 10T1/2 cells can differentiate into 
antagonizes FGF2/FGFR1 signaling without interacting with 
either the soluble growth factor or the receptor (Hasselaar and 
Sage, 1992; Kupprion et al., 1998; Motamed et al., 2003). In 
addition to controlling growth factor signaling, SPARC also 
orchestrates the deposition of the ECM and can modulate   
the interaction between cells and their substratum (Murphy-
Ullrich et al., 1995; Weaver et al., 2008; Bradshaw, 2009). 
Using an orthotopic model of pancreatic cancer, we found   
that pericyte recruitment was decreased in tumors grown in 
SPARC-deficient  mice  (Puolakkainen  et  al.,  2004;  Arnold   
et al., 2010). Though the mechanism underlying this obser-
vation is unknown, the data suggest that SPARC facilitates 
pericyte behavior in vivo.
TGF-1 is a pleiotropic cytokine expressed by vascular 
cells  during  angiogenesis.  TGF-1  is  secreted  in  a  latent 
complex, which must be cleaved or otherwise manipulated   
to expose the active protein (Derynck et al., 1986; Munger   
et  al.,  1999; Annes  et  al.,  2004). The  precise  cellular  re-
sponses induced by active TGF-1 depend on the specific 
TGF- receptors expressed and the level of receptor expres-
sion (Schmierer and Hill, 2007). These responses vary and 
include migration, apoptosis, and proliferation (Goumans et al., 
2003; Guasch et al., 2007; Daly et al., 2008; Yamashita et al., 
2008). TGF-1 receptors are ubiquitous throughout all tis-
sues; therefore, the activation of latent TGF-1 and the bio-
availability of active TGF-1 are tightly regulated (Lyons   
et al., 1988; Imai et al., 1997; Saharinen et al., 1999). Active 
TGF-1 inhibits pericyte migration and induces expression 
and secretion of basement membrane proteins; accordingly, 
TGF-1 signaling in these cells is restricted during angio-
genesis, occurring only upon contact with endothelial cells 
of newly formed vessels (Sato and Rifkin, 1989; Kojima et al., 
1991; Owens, 1995). Although the mechanisms behind this 
regulation are not entirely clear, a plausible scenario is V 
integrin–mediated control of TGF- activation, which could 
occur on the surface of pericytes that have reached the na-
scent endothelial tube.
Pericytes  express  TGF-  receptor  II  (TRII)  and  the 
type II TGF-1 receptor ALK5. In addition to these signaling 
receptors, we show that pericytes also express the accessory 
receptor endoglin. Endoglin, an established regulator of TGF-1 
activity in endothelial cells, interacts with the activated TGF- 
1–TGF- receptor complex and controls endothelial cell be-
havior by affecting TRII/ALK1 and TRII/ALK5 signaling 
and focal adhesion assembly (Conley et al., 2004; Sanz-Rodriguez 
et al., 2004).
In the current study, we sought to determine the mech-
anism  by  which  SPARC  regulates  pericyte  behavior.  We 
report that SPARC promotes pericyte migration by decreas-
ing  TGF-1  activity.  We  found  that  SPARC  is  expressed 
by pericytes in the vasculature of the adult murine pancreas 
and in pancreatic ductal adenocarcinoma (PDAC), where it 
facilitates pericyte migration by preventing endoglin from 
interacting  with  V  integrins,  thereby  repressing TGF-1 
activity. SPARC’s capacity to regulate pericyte recruitment 
highlights its function as a critical component of tissue re-
modeling and angiogenesis.1307 SPARC as a regulator of pericyte migration • Rivera and Brekken
Figure 1.  SPARC is expressed by pericytes in vivo. (A) NG2 expression is restricted to pericytes in adult mouse pancreas. MECA32 labels blood endothe-




lox/lox; C) mice. Insets are magnified on the right. (D–F) PDAC tumors in SPARC
/ animals exhibit more pericyte-free vessels. MECA32 
(green) and anti-NG2 (red) immunofluorescence of SPARC
+/+ (D) and SPARC
/ (E) PDAC mice. An example of a pericyte-free vessel is presented in the 
inset of E and magnified on the right (indicated with a dotted line). (F) Percentage of pericyte-free vessels, vessel number, and relative vessel area (vessel 
area/DAPI area) were assessed in tumors from six SPARC
+/+ and eight SPARC
/ PDAC tumors. Values presented are means + SEM (≥18 20× fields per 
tumor; *, P < 0.005). (G) Isolation of primary pericytes. (top two rows) SPARC
+/+ and SPARC
/ pericytes express NG2 and desmin. Note that a subpopu-
lation of these cells express -SMA. (bottom) primary pericytes induce bEnd.3 cord formation. bEnd.3 cells were plated onto matrigel-coated chamber 
slides alone or in the presence of SPARC
+/+ or SPARC
/ pericytes in triplicate wells. Cord formation was assessed after 17 h. The mean number of cords, 
number of branch points, and cord widths were quantitated from five 10× fields per well. Experiment shown is representative of three independent experi-
ments. Errors bars represent SEM (*, P < 0.0001). WT, SPARC
+/+; KO, SPARC
/. Epifluorescent images are presented in A–E and the top two rows of G. 
Nikon confocal images are presented in bottom row of G (see Materials and methods).
mesenchymal lineages (Lien et al., 2006; Crisan et al., 2008; 
Lee et al., 2008a; Qu et al., 2008; Boeuf et al., 2009). These 
cells also function as pericytes when co-cultured with endothe-
lial cells (Hirschi et al., 1998; Darland and D’Amore, 2001).   
Using our transwell assay, we found that TGF-1 could inhibit 
both SPARC
+/+ pericyte and 10T1/2 cell migration (Fig. 3 A). JCB • VOLUME 193 • NUMBER 7 • 2011   1308
responding  to  endogenous  TGF-1.  For  this,  we  examined 
phosphorylated  SMAD2  (pSMAD2)  in  response  to  shRNA-
mediated knockdown of TGF-1. We found that knockdown of 
TGF-1 reduced SMAD2 phosphorylation only in SPARC
/ 
pericytes but did not inhibit their capacity to respond to exog-
enous TGF-1 (Fig. S3 C and Fig. 4 D). Finally, using TGF-1 
knockdown, we found that endogenous TGF-1 was required 
for the migration phenotype of SPARC
/ pericytes (Fig. 4 F). 
Thus, SPARC reduces activation of endogenous TGF-1.
SPARC interacts with the TGF- accessory 
receptor endoglin
SPARC is a secreted glycoprotein; therefore, we hypothesized 
that control of TGF-1 activity may be mediated through inter-
actions with TGF-1 receptors. SPARC can interact with a sol-
uble form of TRII but only in the presence of recombinant 
TGF-1 (Francki et al., 2004). TGF-1 binds sequentially to its 
receptors: active TGF-1 first binds to TRII, which can be in 
a heteromeric complex with endoglin, which then recruits a 
type I receptor, such as ALK5. We immunoprecipitated each of 
these receptors from 10T1/2 cells and found that SPARC spe-
cifically coprecipitated with endoglin (Fig. 5 B). SPARC was 
also detected in endoglin immune complexes from SPARC
+/+ 
pericytes (Fig. 5 B, right). We confirmed this interaction using 
solid-phase binding assays (Fig. 5 C). Furthermore, immuno-
fluorescent  staining  of  primary  SPARC
+/+  pericytes  revealed 
that SPARC and endoglin associate in distinct punctate structures 
(Fig. 5 A). This interaction links SPARC to TGF-1 signaling.
Endoglin localizes to focal complexes  
in SPARC-deficient pericytes  
and blunts migration
The function of endoglin in TGF-1 signaling is unclear; how-
ever, endoglin has been shown to modulate SMAD phosphory-
lation as well as control cell adhesion and migration, presumably 
through regulating the composition of focal adhesion complexes 
(Gougos et al., 1992; Conley et al., 2004; Koleva et al., 2006; 
To determine whether TGF- was responsible for the migration   
phenotype of SPARC
/ pericytes, we used a TGF-–neutralizing   
antibody. Surprisingly, TGF- neutralization enhanced the 
migration of SPARC
/ cells only (Fig. 3 B and Fig. S2 A). The 
ALK5 inhibitor SB431542 had a similar effect, suggesting that 
TGF- receptor activity is enhanced in the absence of SPARC 
expression (Fig. 3 C). We next attempted to recapitulate our 
findings using 10T1/2 cells. We found that shRNA-mediated   
knockdown  of  SPARC  impaired  10T1/2  cell  migration  in  a 
TGF-–dependent manner (Fig. 3 D and Fig. S2 B). Further-
more, neutralization of SPARC using a monoclonal antibody 
reduced 10T1/2 cell migration in a TGF-–dependent manner 
(Fig. 3 E). Thus, SPARC prevents TGF-–dependent attenua-
tion of pericyte migration.
We found that TGF-1 could reduce SPARC
+/+ pericyte   
and  10T1/2  cell  migration  and,  therefore,  hypothesized  that 
increased  TGF-1  expression  in  SPARC
/  pericytes  was   
responsible for their migration phenotype. Surprisingly, analysis   
of TGF-1 in cell lysates and conditioned media revealed no 
differences in TGF-1 levels in SPARC
+/+ and SPARC
/ peri-
cytes (Fig. 4 A). RT-PCR also revealed no difference in TGF-1 
expression between SPARC
+/+ and SPARC
/ pericytes (Fig. 4 B).   
However, we did observe an increase in PAI1 expression in 
SPARC
/ pericytes, which is a canonical TGF-1 response 
gene (Fig. 4 B). Using quantitative PCR (qPCR), we confirmed 
that SPARC reduced the expression of canonical TGF-1 re-
sponse genes in pericytes (Fig. 4 C). Interestingly, SPARC
/ 
pericytes seemed to be more sensitive to exogenous TGF-1 
(Fig. S3 B). As TGF-1 signaling is initiated at the cell surface, 
we hypothesized that SPARC
/ pericytes had more surface- 
associated TGF-1. Indeed, we observed more TGF-1 on the 
surfaces of nonpermeabilized SPARC
/ pericytes (Fig. S3 A). 
We also assessed the level of surface-associated TGF-1 using 
an impermeable cross-linker. We found that SPARC
/ pericytes 
had more surface-associated TGF-1 compared with SPARC
+/+ 
cells, a feature that was reversed by recombinant SPARC (Fig. 4 E).   
We next tested the possibility that SPARC
/ pericytes were 
Figure 2.  Pericytes exhibit defective transwell migration in the absence of SPARC. (A) SPARC
/ pericytes exhibit impaired migration. Cells were allowed to 
migrate in the presence of BSA or purified SPARC. *, P < 0.02. (B) Knockdown of SPARC in primary pericytes reduces migration. Cells were transfected with 
the indicated shRNA (left) 48 h before use or allowed to migrate in the presence of anti-SPARC or control IgG. *, P < 0.05 versus controls. (C) Exogenous 
SPARC does not affect SPARC
+/+ pericyte migration. Migration of SPARC
+/+ pericytes in the presence or absence of recombinant human SPARC (hSP) was de-
termined. WT, SPARC
+/+; KO, SPARC
/; mSP, mouse SPARC. Experiments were performed in duplicate; means are represented. Error bars represent SEM.1309 SPARC as a regulator of pericyte migration • Rivera and Brekken
decreased  SMAD2  phosphorylation  in  SPARC
/,  but  not 
SPARC
+/+, pericytes (Fig. 6 D).
We then asked whether endoglin participates in the migra-
tion phenotype of SPARC
/ pericytes. To test this, we used 
endoglin shRNA in 10T1/2 cells while targeting SPARC with 
either shRNA or a monoclonal antibody in a transwell assay. 
Endoglin knockdown had no effect on 10T1/2 cells when 
SPARC was not manipulated (e.g., control shRNA or control 
antibody; Fig. 6, E and F). However, knockdown of endoglin 
increased migration of cells transfected with SPARC shRNA or 
treated with an anti-SPARC antibody. Collectively, these results 
suggest focal complex–associated endoglin facilitates TGF-1 
activity and that SPARC functions to limit this process.
V integrins interact with endoglin and 
positively regulate SMAD2 phosphorylation 
in SPARC-deficient pericytes
Endoglin does not directly activate TGF-1–mediated processes 
(Koleva et al., 2006; Lee et al., 2008b). Association of endoglin 
with focal complexes and the regulation of migration and SMAD2 
phosphorylation in SPARC
/, but not SPARC
+/+, pericytes sug-
gested that, perhaps, in the absence of SPARC, endoglin was 
Lee et al., 2008b). Therefore, we explored whether endoglin ex-
hibited differences in localization and activity in SPARC-deficient 
pericytes. We first assessed endoglin association with focal com-
plexes of spreading SPARC
+/+ or SPARC
/ pericytes. Vinculin-
rich focal complexes were observed in spreading SPARC
+/+ and 
SPARC
/ pericytes (Fig. 6 A). We found that endoglin localized 
with focal complexes only in SPARC
/ pericytes (Fig. 6 A, insets 
and magnified images). To determine whether endoglin aber-
rantly associates with focal adhesion machinery in the absence of 
focal  complexes,  we  immunoprecipitated  endoglin  complexes 
from SPARC
+/+ and SPARC
/ pericytes in suspension or seeded 
on plastic or fibronectin and probed for FAK, as FAK becomes 
incorporated  into  maturing  focal  complexes  (Kornberg  et  al., 
1992). We found that FAK was present in endoglin immune com-
plexes from SPARC
/, but not SPARC
+/+, pericytes and that this 
association required cell adhesion (Fig. 6 B). We confirmed that 
FAK-associated endoglin was SPARC dependent using recom-
binant SPARC (Fig. 6 C). These results suggest that SPARC pre-
vents endoglin from incorporating into focal complexes.
Next, we asked whether endoglin was required for ele-
vated basal SMAD2 phosphorylation in SPARC
/ pericytes. 
We found shRNA-mediated knockdown of endoglin resulted in 
Figure 3.  TGF- limits transwell migration of pericytes in the absence of SPARC. (A) TGF-1 reduces SPARC
+/+ pericyte and 10T1/2 cell migration. Cells 
were allowed to migrate in the presence of vehicle or 1 ng/ml TGF-1. Error bars represent SEM (**, P < 0.001 vs. vehicle). (B) Neutralization of TGF- 
enhances SPARC
/, but not SPARC
+/+, pericyte migration. Cell migration in the presence of no stimulation (NS), 10 nM PDGF-BB, 25 ng/ml anti–TGF- 
IgG (–TGF- IgG), or 50 ng/ml VEGF-A was assessed. (C) Inhibition of ALK5 enhances SPARC
/ pericyte migration. The effect of 25 ng/ml –TGF- or 
control IgG, 10 µM ALK5 inhibitor (SB431542), or ALK5 inhibitor vehicle alone (vehicle) on the migration of primary pericytes is shown. (D) Knockdown 
of SPARC in 10T1/2 cells impairs migration in a TGF-–dependent manner. 10T1/2 cells were transfected with SPARC or control shRNA for 48 h and then 
used in a transwell assay. Western blot to confirm knockdown is presented on the left. Cells were allowed to migrate in the presence of 25 ng/ml –TGF- 
IgG where indicated. (E) Anti-SPARC IgG reduces 10T1/2 cell migration in a TGF-–dependent manner. 10T1/2 cells were allowed to migrate in the pres-
ence of 25 ng/ml control IgG, 25 ng/ml anti-SPARC IgG (clone 293; -SPARC IgG), 25 ng/ml –TGF- IgG plus 25 ng/ml -SPARC IgG, or 25 ng/ml 
–TGF- IgG plus 25 ng/ml control IgG for 6 h. All experiments were performed in triplicate at least twice with similar results. Mean values are presented. 
Error bars represent SEM (*, P < 0.05). WT, SPARC
+/+; KO, SPARC
/. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.JCB • VOLUME 193 • NUMBER 7 • 2011   1310
We also found no differences in V integrin–mediated migration 
between SPARC
+/+ and SPARC
/ pericytes (Fig. 7 B). We then 
asked whether endoglin-associated V integrins are required for 
the increased basal TGF-1 activity observed in SPARC
/ peri-
cytes. Treatment of cells with an V integrin–blocking antibody 
reduced SMAD2 phosphorylation in SPARC
/, but not SPARC
+/+, 
pericytes, though the extent of inhibition was not as great as that 
seen in cells treated with SB431542 (Fig. 7 C). We then examined 
whether V integrin was present in endoglin immune complexes. 
V  integrin  was  detected  in  SPARC
/  pericyte  immune  com-
plexes regardless of whether cells were adherent or in suspension   
(Fig. 7 D). V integrin was also detected in SPARC
+/+ pericyte 
cooperating with factors that positively regulate TGF- signaling.   
V integrins facilitate cell adhesion and migration and can   
directly activate latent TGF-1 (Delannet et al., 1994; Klemke 
et al., 1994; Liaw et al., 1995; Stefansson and Lawrence, 1996). 
Therefore, we sought to determine whether endoglin cooperated 
with V integrins to enhance TGF-1 activity in SPARC
/ peri-
cytes. We found that SPARC
+/+ and SPARC
/ pericytes express 
similar levels of V integrins by RT-PCR and flow cytometry 
(Fig. 7 A). Furthermore, SPARC
+/+ and SPARC
/ pericytes ex-
press  integrin subunits that have been implicated to participate 
with V integrin in mediating TGF-1 activation (Munger et al., 
1998; Mu et al., 2002; Ludbrook et al., 2003; Annes et al., 2004). 
Figure 4.  SPARC
/ pericytes exhibit increased basal TGF- activity. (A) SPARC
+/+ and SPARC
/ pericytes express similar levels of TGF-1 protein. Cells 
lysates and conditioned media were harvested after culture for the indicated times. TGF-1 concentration was detected using a TGF-1 ELISA. (B) Primary 
SPARC
+/+ and SPARC
/ pericytes express similar levels of TGF-1 message. RT-PCR for the indicated genes was performed with cDNA harvested from   
cells cultured on either plastic or fibronectin. (C) SPARC
/ pericytes exhibit higher canonical TGF-1 response gene expression. qPCR was performed 
on cells treated as indicated. Error bars represent SEM (*, P < 0.05 vs. WT). (D) Endogenous TGF-1 induces SMAD2 phosphorylation in SPARC
/ 
pericytes. Cells were transfected with either negative control (NC) or TGF-1 shRNA where indicated 48 h before preparing lysates. Cells treated with 
TGF-1 received treatment 5 h before cell lysis. Lysates were probed for tSMAD2 and pSMAD2 by SDS-PAGE and Western blotting. pSMAD2 levels were 
normalized with ImageJ software. (E) SPARC
/ pericytes retain more surface TGF-1 than SPARC
+/+ counterparts. Surface proteins were labeled, purified, 
and subjected to SDS-PAGE and probed for the indicated proteins by Western blotting (left). Recombinant SPARC decreases TGF-1 levels on the surface of 
SPARC
/ pericytes (right). Cells were cultured as in C before surface protein extraction and Western blot analysis. Pixel area under the curve was gener-
ated using ImageJ software, and these values are presented under their respective bands. (F) Knockdown (KD) of TGF-1 enhances migration of SPARC
/ 
pericytes. Cells were transfected with the indicated shRNA for 48 h before use in the transwell assay. Cells were treated with TGF-1 for the duration of 
the assay only. All experiments were performed at least twice with identical results. Mean values are presented. Error bars represent SEM (*, P < 0.05).   
WT, SPARC
+/+; KO, SPARC
/; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; WCL, whole-cell lysate.1311 SPARC as a regulator of pericyte migration • Rivera and Brekken
accessory receptor endoglin. In the absence of SPARC, endo-
glin associates with V integrins and enhances TGF-1 signal-
ing to impair pericyte migration.
During angiogenesis, pericytes migrate to nascent vessels 
where TGF-1 signaling impedes further migration and trig-
gers pericyte-induced vessel quiescence (Courtoy and Boyles, 
1983; Antonelli-Orlidge et al., 1989; Sato and Rifkin, 1989; 
Stefansson and Lawrence, 1996; Hirschi et al., 1998; Darland 
and D’Amore, 2001). As TGF-1 is present in the extracellular 
milieu throughout endothelial tube formation, the capacity of 
pericytes to respond to TGF-1 must be regulated spatially. 
Mechanisms that contribute to such regulation remain unknown. 
We found that SPARC was expressed in pericytes during vascu-
lar morphogenesis in PDAC, and pericyte recruitment was re-
duced in the absence of SPARC. We propose that SPARC can 
block the capacity of pericytes to respond to TGF-1 during angio-
genesis and, thus, facilitate cell migration to nascent blood ves-
sels, based on the following observations: First, SPARC-deficient 
immune complexes, albeit at lower levels (Fig. 7 D). As the level 
of V integrin present in SPARC
/ endoglin immune complexes 
was greater than that seen in SPARC
+/+ complexes, we thought that 
SPARC may limit V integrin and endoglin association. Thus, we 
assessed the effect of adding recombinant SPARC to SPARC
/ 
pericytes on the amount of endoglin-associated V integrin. We 
found that exogenous SPARC reduced endoglin-associated V in-
tegrin while having no effect on total V integrin levels (Fig. 7 E). 
Collectively, these results show that SPARC, by blocking endoglin 
from interacting with V integrins, can reduce TGF- activity.
Discussion
SPARC reduces the capacity of pericytes 
to perceive TGF-1
In  the  current  study,  we  demonstrate  that  SPARC  promotes 
pericyte  migration  by  reducing  TGF-1–induced  responses.   
To perform this function, SPARC interacts with the TGF-1 
Figure 5.  SPARC interacts with TGF-1 accessory receptor endoglin. (A) SPARC and endoglin colocalize in primary SPARC
+/+ pericytes. Pericytes adhered 
to silane-coated slides were subjected to immunofluorescence with anti-SPARC IgG and antiendoglin IgG. DAPI was used to visualize nuclei. Inset shows co-
localization. Arrows indicate punctuate areas of colocalization. Bars, 10 µm. (B) SPARC coprecipitates with endoglin immune complexes. 10T1/2 cell lysates 
were incubated anti-ALK5, antiendoglin, anti-SPARC, or anti-TRII (RII) IgGs. IgG-bound complexes were precipitated with protein A/G agarose beads. The 
indicated complexes were subjected to SDS-PAGE and probed for the indicated proteins by Western blotting. Asterisks indicate the target protein. Molecular 
masses in kilodaltons are labeled. IgG VH corresponds to the 50-kD band. IP, immunoprecipitation target; WB, Western blot target. SPARC was also detected 
in endoglin immune complexes from SPARC
+/+ pericytes (WT). (C) SPARC interacts with endoglin in solid-phase binding assays. 96-well plates were coated 
with either 5 µg/ml endoglin (left), 5 µg/ml SPARC (right), or control serum. Soluble SPARC or endoglin was added to the indicated plate in triplicate at 
increasing concentrations and detected using anti-SPARC or antiendoglin IgG. All experiments were performed at least three times with identical results. 
Binding is expressed as mean absorbance. Errors bars represent SEM. Epifluorescent images are presented in A. WCL, whole-cell lysate.JCB • VOLUME 193 • NUMBER 7 • 2011   1312
increased basal TGF-1–induced SMAD2 phosphorylation and 
activity. Third, SPARC deficiency resulted in increased TGF-1 
associated with pericyte surfaces while not effecting levels   
of TGF-1 mRNA, cytosolic TGF-1, or secreted TGF-1. 
pericytes migrated less in vitro, an effect that was reversed when 
adding back recombinant SPARC, blocking TGF-–TGF- re-
ceptor ligation, inhibiting ALK5 kinase activity, or knocking 
down TGF-1. Second, SPARC-deficient pericytes exhibited 
Figure 6.  Endoglin associates with focal complexes in SPARC
/ pericytes. (A) Endoglin colocalizes with vinculin plaques in SPARC
/ pericytes. 
Cells were plated onto fibronectin-coated slides for 120 min. Cells were fixed and stained with antivinculin and antiendoglin IgG and visualized using 
a confocal microscope (TCS SP5; maximum intensity projections from 16–0.15-µm z stacks per stain were generated using ImageJ software and are 
presented). ZY planes are presented from the regions between the asterisks in split channel images. Bars, 20 µm. (B) FAK coprecipitates with endoglin 
immune complexes from SPARC
/ pericytes. Endoglin was immunoprecipitated from lysates harvested from cells in suspension (S) or adhered to plastic 
(P) or fibronectin (F). Complexes were then probed for FAK or endoglin by SDS-PAGE and Western blotting. WCL, whole-cell lysates. (C) Recombinant 
SPARC reduces FAK-associated endoglin in SPARC
/ pericytes. SPARC
/ pericytes were incubated with either BSA or recombinant SPARC at 0, 50, or   
150 µg/ml for 6 h. Endoglin was immunoprecipitated from cell lysates, and complexes were subjected to SDS-PAGE and Western blotting for endoglin 
and FAK. (D) Knockdown of endoglin reduces SMAD2 phosphorylation in SPARC
/ pericytes. Pericytes were transfected with endoglin or control 
shRNA for 48 h. Lysates were prepared and subjected to SDS-PAGE. tSMAD2 and pSMAD2 were detected by Western blotting. pSMAD2 levels 
were normalized with ImageJ software. (E) Knockdown of endoglin reverses the effect of silencing SPARC on 10T1/2 cell transwell migration. Cells 
were transfected with the indicated shRNA for 48 h and then allowed to migrate in the indicated conditions. (F) Knockdown of endoglin reverses the 
effect of neutralizing SPARC on 10T1/2 cell transwell migration. Cells were transfected as in E and allowed to migrate in the presence or absence 
of 25 ng/ml anti-SPARC or control IgG as indicated. All experiments were performed at least twice with identical results. Mean values are presented. 
Error bars represent SEM (*, P < 0.05). WT, SPARC
+/+; KO, SPARC
/. Leica confocal images are presented in A (see Materials and methods).   
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; cntl, control; end, endoglin.1313 SPARC as a regulator of pericyte migration • Rivera and Brekken
TGF-1 activity in pericytes, a finding that suggests its effects 
may  be  dependent  on  this  accessory  receptor  in  other  cells 
types. Studies assessing the contribution of TGF-1 accessory 
receptors to SPARC activity will undoubtedly shed light on why 
SPARC and TGF-1 expression temporally overlap during de-
velopment and disease.
SPARC controls pericyte migration by 
regulating endoglin function
Endoglin  is  a  critical  component  of  the  TGF-–signaling   
machinery and is required for development of the vasculature. 
Genetic ablation of endoglin in mice results in embryonic le-
thality from defective vascular remodeling, a phenotype that re-
sembles that of TGF-1 KO mice (Dickson et al., 1995; Bourdeau 
et al., 1999; Li et al., 1999; Arthur et al., 2000). Interestingly, en-
doglin is not required for formation of the initial vascular plexus, 
SPARC thus may control TGF-1 perception by pericytes 
during  blood  vessel  formation.  Interestingly,  we  found  that 
SPARC
/ pericytes were more sensitive to exogenous TGF-1   
(Fig. S3 B). Integrins V3 and V5 have been shown to   
promote TGF-1 signaling and target gene expression by en-
hancing  TGF-  receptor  activity  through  direct  receptor 
interactions; therefore, it seems reasonable that endoglin–V 
integrin complexes have an amplified response to exogenous 
TGF-1 (Scaffidi et al., 2004; Asano et al., 2006a,b; Galliher 
and Schiemann, 2006).
In spite of our findings, the precise mechanism through 
which SPARC regulates TGF-1 activity is still unclear. This is 
because of several independent studies with opposing conclu-
sions on the effect of SPARC on TGF-1 activity (Schiemann 
et al., 2003; Francki et al., 2004; Chlenski et al., 2007). In the 
current study, we found that SPARC required endoglin to regulate 
Figure 7.  V integrin interacts with endoglin and mediates TGF- activity in primary SPARC
/ pericytes. (A) Integrin expression profile of primary peri-
cytes. RT-PCR detection of SPARC, V integrin (itgav), 1 integrin (itgb1), 3 integrin (itgb3), 6 integrin (itgb6), and RPS6 (rps6). (right) Primary SPARC
+/+ 
and SPARC
/ pericytes express V integrins at their surfaces. 500,000 were seeded onto fibronectin-coated dishes and allowed to adhere overnight in 
0.75% serum media. Cells were harvested and prepared for FACS analysis using anti–V integrin IgG (RMV-7) at 20 µg/ml. Control cells were stained 
with secondary alone. av, avidin; NC, negative control. (B) V integrins regulate transwell migration of primary pericytes. Pericytes were allowed to mi-
grate in the presence of 20 µg/ml RMV-7 or 20 µg/ml control IgG. Mean values are presented. Error bars represent SEM (*, P <0.05). (C) V integrins 
regulate TGF- activity in primary SPARC
/ pericytes. Primary SPARC
+/+ or SPARC
/ pericytes were incubated overnight in 1.5% serum in the presence of   
10 µM SB431542, 20 µg/ml RMV-7, 20 µg/ml control IgG, or vehicle alone as indicated. pSMAD2 and tSMAD2 levels were determined by SDS-PAGE 
and Western blotting. pSMAD2 levels were normalized to tSMAD2 using ImageJ software. (D) V integrins associate with endoglin in SPARC
/ pericytes. 
Endoglin was immunoprecipitated from lysates harvested from cells in suspension (S) or adhered to plastic (P) or fibronectin (F). Complexes were then 
subjected to SDS-PAGE and probed for V integrin by Western blotting. (E) SPARC blocks the V integrin–endoglin interaction. SPARC
/ pericytes were 
incubated with either BSA or recombinant SPARC (rSPARC) at the indicated concentrations for 6 h. Endoglin was immunoprecipitated from cell lysates, and 
complexes were subjected to SDS-PAGE. V integrin and SPARC levels were determined by Western blotting. Coprecipitating V integrin was normalized 
to V integrin in whole-cell lysates (WCL) using ImageJ software. IP, immunoprecipitation. All experiments were repeated at least twice with the same results. 
WT, SPARC
+/+; KO, SPARC
/.JCB • VOLUME 193 • NUMBER 7 • 2011   1314
Activated  TGF-  receptors  regulate  pericyte  migration 
via their inherent kinase activity; for example, TGF-1 inhibits 
migration by stimulating ALK5-dependent phosphorylation of 
SMADs and p38 (Feinberg et al., 2004). TGF-1 signaling is 
potentiated  upon  recruitment  of  TGF-  receptors  into  focal 
complexes, though the mechanisms that drive receptor recruitment 
to these structures are unclear (Scaffidi et al., 2004; Asano et al., 
2006b; Galliher and Schiemann, 2006; Lee et al., 2010). In ad-
dition to interacting with intracellular components of focal adhe-
sions, endoglin also interacts with TRII in the absence of a 
bound ligand, a feature that suggests it may serve to bridge the 
gap between TGF-1 signaling and focal complexes (Barbara 
et al., 1999; Guerrero-Esteo et al., 2002). We found that in the 
absence  of  SPARC,  endoglin  facilitated  increased  SMAD2 
phosphorylation. As endoglin does not exhibit kinase acti-
vity, this was likely the result of TGF- receptor recruitment to 
focal complexes.
TRII/ALK5 signaling is required for the decreased migra-
tion observed in the absence of SPARC; however, it remains to be 
determined whether endoglin localization to focal complexes is 
dependent on TRII/ALK5 activity. In our model, endoglin links 
these receptors to TGF-1, which predicts that association of en-
doglin with focal complexes is upstream of any kinase activity.
Endoglin links TGF- receptors to V 
integrin complexes
The question then becomes: how does focal complex–associated 
endoglin enhance TGF-1 activity? We propose that endoglin 
bridges TGF- receptors and V integrin–associated TGF-1. 
Our results support this proposal based on the following: First, 
V integrins were found in the endoglin-enriched focal com-
plexes observed in the absence of SPARC. Second, recombi-
nant SPARC increased migration of SPARC
/ pericytes while 
decreasing  endoglin–V  integrin  complex  formation.  Third, 
V integrins enhanced ALK5/TRII activity but only in the 
absence of SPARC. These results are in line with other studies 
demonstrating that SPARC can interact with and regulate focal 
adhesion proteins (Murphy-Ullrich et al., 1995; Motamed and 
Sage, 1998; Shi et al., 2004; Barker et al., 2005; Weaver et al., 
2006, 2008; Nie et al., 2008). Recently, SPARC was shown to 
interact with 1 integrins (Nie et al., 2008; Weaver et al., 2008). 
Our data do not rule out the possibility that SPARC interacts 
with endoglin and  integrins to control V integrin–TGF-1 sig-
naling. Indeed, V1 integrin can bind to the latency-associated 
peptide (LAP), though actual activation of latent TGF-1 has 
yet to be demonstrated clearly (Munger et al., 1998).
TGF-1 LAP contains an RGD domain to which all five 
V integrins can bind (Munger et al., 1999; Mu et al., 2002; 
Ludbrook et al., 2003). Furthermore, interaction of latent TGF-1 
with V3, V5, V6, and V8 results in the presentation 
of TGF-1 to its receptors. In our model, in the absence of 
SPARC, V integrins interact with latent TGF-1 and present 
the active protein to endoglin-associated TGF- receptors, facili-
tating the inhibition of migration. In wild-type (WT) cells, SPARC 
interacts with endoglin and prevents it from recruiting TGF- re-
ceptors to V integrin–latent TGF-1 complexes, promoting peri-
cyte migration (Fig. 8).
rather vessel defects result from lack of mural cell recruitment 
to the early vascular network. Vascular cell expression of endo-
glin is increased during angiogenesis; however, the function of 
endoglin in pericytes has been unclear. Similarly, V integrin is 
expressed by mural cells, but its function on these cells during 
angiogenesis is unclear (Stawowy et al., 2003; Gao and Brigstock, 
2004). Our results thus place these proteins together with SPARC 
in a mechanism to regulate the activation of latent TGF-1. We 
found that endoglin was required for the enhancement of TGF-–
induced responses we observed in the absence of SPARC. 
SPARC also prevented endoglin from associating with V inte-
grins, likely via a mechanism involving direct interaction with 
the extracellular domain of endoglin. We propose that the ca-
pacity of endoglin to block pericyte migration in the absence of 
SPARC requires its association with focal complex–associated 
proteins. In support of this, we found that recombinant SPARC 
disrupted endoglin–V integrin and endoglin–FAK complex for-
mation, with disruption of endoglin–FAK complexes by SPARC 
being more efficient. Other groups have shown that FAK and 
other  focal  adhesion  proteins  dissociate  from  integrins  after   
internalization (Finnemann, 2003; Pellinen and Ivaska, 2006; 
Thomas et al., 2010). We found that endoglin–V integrin com-
plexes were not dependent on the formation of focal adhesions, 
a finding that suggests these complexes persist upon integrin   
internalization. Such a scenario would result in a pool of   
endoglin–V complexes that were not associated with focal 
adhesions and might be less sensitive to SPARC-induced dis-
sociation. These complexes would likely make it difficult to dis-
cern complex dissociation at focal adhesions in our assay. Thus, 
we would predict that relatively high concentrations of SPARC 
would be required to perturb endoglin–V complexes (Fig. 7 E). 
Conversely,  we  found  endoglin–FAK  complexes  only  when 
SPARC
/ pericytes were allowed to form focal adhesions. This 
suggests that prevention of endoglin from interacting with focal 
adhesion proteins (e.g., with SPARC) would result in the dis-
ruption of endoglin–FAK complexes. Indeed, we saw endoglin–
FAK complex dissociation at a threefold lower concentration of 
SPARC compared with endoglin–V complexes.
Endoglin can control cell migration, at least in part, via 
intracellular interactions. Previous studies have demonstrated 
direct  interaction  between  the  cytoplasmic  PDZ-interacting 
motif of endoglin and GIPC1. This interaction resulted in re-
tention of surface-associated endoglin in focal complexes, in-
creased SMAD phosphorylation, and reduced cell migration 
(Lee et al., 2010; Ray et al., 2010). The cytoplasmic domain of 
endoglin also facilitates blockade of zyxin and ZRP-1 recruit-
ment into maturing focal complexes; thus, endoglin may reduce 
migration as a result of suboptimal focal adhesion assembly 
(Conley et al., 2004; Sanz-Rodriguez et al., 2004). In addition 
to intracellular interactions, our results demonstrate that en-
doglin can influence cell migration via extracellular interac-
tions. Determining whether the effect of SPARC on endoglin 
activity requires the cytoplasmic tail of endoglin and sub-
sequent changes in focal complex assembly will provide in-
sight on the mechanism of SPARC control of pericyte behavior 
and may help explain how SPARC regulates cell morphology 
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SPARC can be cleaved by plasmin, whose own expression is 
temporally  regulated  throughout  angiogenesis  (Lane  et  al., 
1992, 1994; Iruela-Arispe et al., 1995). Furthermore, the inte-
grin profile of pericytes changes during angiogenesis, a phe-
nomenon that may also affect SPARC-mediated blockade of 
TGF-1.  Experiments  addressing  how  these  events  regulate 
SPARC activity will undoubtedly yield important insights on 







lox/lox)  mice  were  crossed  with 
SPARC
+/+ or SPARC
/ mice to produce WT PDAC or SPARC-null PDAC 
(knockout [KO] PDAC) mice. For tumor analyses, mice were sacrificed 
once becoming moribund, with at least six mice per group. Tumors were 
preserved in formalin or snap frozen using liquid nitrogen. Animal experi-
ments were performed at the University of Texas Southwestern Medical 
Center at Dallas in compliance with the Animal Welfare Act, the Public 
Health Service Policy, and the U.S. Government Principles Regarding the 
Care and Use of Animals.
Antibodies
Antibodies to the following proteins were used for indirect immunofluores-
cent microscopy: -SMA (NeoMarkers), NG2 (AB5320; Millipore), des-
min  (Ab907;  Millipore),  vinculin  (V4139;  Sigma-Aldrich),  MECA32, 
SPARC (R&D Systems), total TGF- (SC146; Santa Cruz Biotechnology, 
Inc.), and endoglin (MJ7/18). For function-blocking assays, a pan–TGF-–
neutralizing antibody was purchased from R&D Systems (1D11), an V6-
blocking antibody was a gift from D. Sheppard (University of California, 
San Francisco, San Francisco, CA), and an V integrin–blocking antibody 
was purchased from BioLegend (RMV-7). The hybridomas that produce 
mAb293 and mAb303 were grown in our laboratory and purified by pro-
tein A chromatography. For Western blots, ALK5 (SC-398; Santa Cruz Bio-
technology, Inc.), TRII (SC-220; Santa Cruz Biotechnology, Inc.), endoglin 
(clone MJ7/18), V integrin (AB1930; Millipore), FAK (3285; Cell Signal-
ing Technology), phospho-SMAD2 (AB3849 serine 465/467; Millipore), 
and total SMAD2 (tSMAD2; 3107; Cell Signaling Technology) were used. 
For solid-phase binding assays, endoglin (MJ7/18) and SPARC (mAb 236) 
There  are  currently  two  known  mechanisms  of  V   
integrin–mediated activation of TGF-1, one requiring pro-
tease activity and the other being protease independent. Protease-
independent activation of latent TGF-1 has been shown to occur 
with V3, V5, and V6 integrins (Ludbrook et al., 2003; 
Annes et al., 2004; Wipff et al., 2007). In this mechanism, trac-
tion is proposed to induce the release of active TGF-1 from the 
latent complex. Binding of active TGF-1 requires TGF- re-
ceptors to be in close proximity, a feature that explains why re-
lease of active TGF-1 into the culture media is never observed. 
Interestingly, we failed to detect changes in active TGF-1 in 
culture media, suggesting this mechanism may be involved.
Protease-dependent activation of TGF-1 has only been 
demonstrated with V8: V8 binds latent TGF1 and re-
cruits MT1-MMP, which then releases active TGF-1 via pro-
teolytic cleavage of LAP (Mu et al., 2002). As we failed to 
detect changes in TGF-1 in culture media, it is unlikely that an 
V8/MT1-MMP axis is involved in SPARC-mediated regula-
tion of pericyte behavior.
Conclusion
Endoglin is an established regulator of endothelial cell behav-
ior. We describe here a novel mechanism in which endoglin co-
operates with SPARC to regulate pericyte responses to TGF-1. 
Our findings suggest that during angiogenesis, SPARC func-
tions to restrict pericyte perception of TGF-1 in the angiogenic 
milieu through its interaction with endoglin. Such control is 
critical, as TGF-1 is present early in the angiogenic cascade, 
yet TGF-1 signaling in pericytes must occur after formation of 
endothelial tubes.
SPARC was expressed in both resting and mobilized peri-
cytes, an observation that suggests the function of SPARC is 
also controlled. Indeed, previous studies have demonstrated that 
Figure  8.  Proposed  model  of  how  SPARC 
regulates pericyte migration through endoglin 
and TGF-1. (A) TGF-1 is secreted as a latent 
protein associated with LAP and cannot bind 
TGF-  receptors.  LAP  binds  V  integrins  via 
its RGD motif. SPARC binds endoglin, block-
ing its association with V integrins, thereby 
promoting  pericyte  migration.  (B)  In  the  ab-
sence of SPARC, endoglin bridges TRII/ALK5 
with  V  integrin–associated  active  TGF-1 
and promotes signals that blocks pericyte mi-
gration. This model predicts that as pericytes 
come into contact with nascent blood vessels, 
SPARC is somehow removed from the receptor 
complex, allowing TGF- receptors to engage   
V integrin–bound TGF-1. During angiogene-
sis, SPARC undergoes proteolysis in a regulated 
fashion  (Lane  et  al.,  1994).  This  proteolysis 
produces SPARC fragments with various acti-
vities and, thus, may provide a mechanism for 
controlling SPARC–endoglin interactions.JCB • VOLUME 193 • NUMBER 7 • 2011   1316
the kit. For qPCR expression analyses, fold change was calculated using the 
 cycle threshold method, in which WT at 0 pg/ml was the reference sam-
ple, and GAPDH was the reference gene. Sample preparation for qPCR ex-
pression analyses were as follows: serum-starved primary pericytes were 
seeded at 100,000 cells per well in fibronectin-coated 6-well tissue-culture 
plates in triplicate. Active TGF-1 purchased from PeproTech was added to 
serum-starved pericytes at final concentrations of 0, 50, and 5,000 pg/ml. 
Cells were then incubated for 17 h at 37°C. RNA was harvested using 
TRIZOL reagent (Sigma-Aldrich). cDNA was synthesized using iScript (Bio-
Rad Laboratories). 12.5 ng cDNA was used per 96-well PCR plate well, with 
each tissue-culture plate well represented in three individual PCR plate wells. 
The following primer sets were used for qPCR or RT-PCR: CTGF forward,   
5-AGCCTCAAACTCCAAACACC-3, and reverse, 5-CAACAGGGATTT-
GACCAC-3;  PAI-1  forward,  5-GACACCCTCAGCATGTTCATC-3,  and   
reverse, 5-AGGGTTGCACTAAACATGTCAG-3; BIGH3 forward, 5-TGAT-
AAGAGGGGACGGTTTG-3, and reverse, 5-ATTGGTGGGAGCAAAAA-
CAG-3; and GAPDH forward, 5-AGAAGGCTGGGGCTCATTTG-3, and 
reverse, 5-AGGTCGGAGTCAACGGATTTG-3.
To assess the effect of SPARC on SPARC
/ pericyte transcription, 
pericytes were cultured for 72 h in the presence or absence of recombinant 
SPARC or BSA control. Media were replaced with fresh SPARC- or BSA- 
containing media every 24 h before RNA extraction.
RT-PCR
Cells were incubated in 0.75% fetal bovine serum–supplemented DME 
overnight before RNA extraction and cDNA synthesis. The following primer 
sets were used for RT-PCR: endoglin (L-endoglin) forward, 5-GCACTCTG-
GTACATCTATTCTCACACACGTGG-3, and reverse, 5-GGGCACTACG-
CCATGCTGCTGGTGG-3;  SPARC  forward,  5-CTGCGTGTGAAGAAG-
ATCCA-3, and reverse, 3-TGGGACAGGTACCCATCAAT-3; ALK5 for-
ward, 5-GGCGACGGCATTACAGTGTT-3, and reverse 5-TGTACATAC-
AAATGGCCTGT-3; TRII forward, 5-GCAAGTTTTGCGATGTGAGA-3,   
and reverse, 5-GGTATCTTCCAGAGTTGAAGC-3; TGF-1 forward, 5-TTG-
CTTCAGCTCCCACAGAGA-3, and reverse, 5-TGGTTGTAGAGGGCAA-
GGAC-3; V integrin: itgav forward 5-GGGTGATCATCTTGGCAGTT-3, 
and reverse, 5-GAACTTGGAGCGGACAGAAG-3; 1 integrin: itgb1 
forward, 5-GTGACCCATTGCAAGGAGAAGGAC-3, and reverse 5-GTC-
ATGAATTATCATTAAAAGTTT-3; 3 integrin: itgb3 forward, 5-CTGGTGTT-
TACCGATGCCAAG-3, and reverse, 5-TGTTGAGGCAGGTGGCATTGA-
AGG-3; 6 integrin: itgb6 forward, 5-CCGGCTGGCCAAAGAGATGT-3, 
and reverse, 5-AGTTAATGGCAAAATGTGCT-3; RPS6: rps6 forward, 5-AA-
GCTCCGCACCTTCTATGAGA-3, and reverse, 5-TGACTGGACTCAGA-
CTTAGAAGTAGAAGC-3; and -actin: actb forward, 5-ATATCGCTGCGCT-
GGTCGTC-3, and reverse, 5-AGGATGGCGTGAGGGAGAGC-3.
Detection of basal SMAD2 phosphorylation
Pericytes were seeded at 100,000 cells per well of 6-well culture plates and 
cultured in 1.5% fetal bovine serum–supplemented DME for 17 h before   
being lysed in 300 µl sample buffer (62.5 mM Tris-HCl, pH 6.8, at 25°C, 2% 
SDS, 10% glycerol, 50 mM DTT, and 0.01% bromophenol blue). Lysates 
were  subjected  to  SDS-PAGE  and  Western  blotting  for  tSMAD2  and   
pSMAD2 (serine 465/467) immediately thereafter.
Immunoprecipitation
10T1/2 cells were lysed in modified radioimmunoprecipitation assay buf-
fer (0.5% deoxycholate, 0.5% SDS, 1% Triton X-100, 10 mM sodium phos-
phate, pH 7.2, 150 mM sodium chloride, and protease inhibitor [Complete 
Mini]). Pericytes were lysed in a milder buffer containing 1% NP-40, 10 mM 
sodium phosphate, pH 7.2, 150 mM sodium chloride, and protease inhibi-
tor (Complete Mini). Lysis was performed on serum-starved adherent cells 
after washing with chilled PBS. Cells were scraped using 1 ml modified   
radioimmunoprecipitation buffer. Lysates were allowed to rotate at 4°C on 
a nutator for 1 h and then vortexed several times before centrifuging at 
13,000 rpm for 10 min to pellet any insoluble material. Lysates were then 
precleared with protein A/G beads (Thermo Fisher Scientific). 200 µg cel-
lular protein in 1 ml lysis buffer was used per immunoprecipitation reac-
tion. 1 µg of the appropriate IgG was added with 20 µl protein A/G bead 
slurry to each sample; each sample was then allowed to rotate overnight 
at 4°C on a nutator. Immunoprecipitated complexes were washed twice in 
lysis buffer and then boiled in sample buffer and subjected to SDS-PAGE 
and Western blot analysis.
Solid-phase binding assays
Wells of 96-well clear-well assay plates were coated with recombinant 
human SPARC, recombinant human endoglin (R&D Systems), or serum 
were used. For immunoprecipitations, SPARC (mAb303), ALK5, TRII (SC-
220), and endoglin (MJ7/18) were used. The hybridomas MECA32 and 
MJ7/18, developed by E.C. Butcher (Stanford University, Palo Alto, CA), 
were obtained from the Developmental Studies Hybridoma Bank, devel-
oped under the auspices of the National Institute of Child Health and   
Human Development, and maintained by The University of Iowa.
Primary pericyte isolation, cell culture, and transfections
Mouse  pancreata  from  4-wk-old  SPARC
+/+  and  SPARC
/  mice  were 
minced and then subjected to digestion with 1% collagenase type 1, DME, 
10 mM Hepes, 1% fetal bovine serum, and PBS at 37°C until a single-cell 
suspension was obtained. Cell suspensions were centrifuged at low speed 
to pellet large debris, resuspended in wash buffer, and passed through a 
70-µm cell strainer. The resulting cell suspension was then incubated with 
sheep anti–rabbit IgG-conjugated magnetic Dynabeads (Invitrogen) and 
rabbit anti-NG2 IgG (Millipore) at 4°C. Dynabeads were preincubated 
with anti-NG2 IgG overnight at 4°C on a nutator and then washed three 
times in wash buffer to remove NaN2. Bead-bound cells were separated 
from unbound cells using a cell separation magnet (IMagnet; BD). Primary 
pericytes were maintained in 10% fetal bovine serum–supplemented DME 
and used between passage 1 and 7 for experiments. 10T1/2 cells were 
used before 10 passages and maintained in 10% fetal bovine serum– 
supplemented DME. Primary pericytes were transfected using Lipofectamine 
2000 (Invitrogen), whereas 10T1/2 cells were transfected using Fugene 
(Roche). For shRNA knockdown of SPARC, endoglin, and TGF-1, shRNA 
expression plasmids were purchased from Sigma-Aldrich (MISSION). 2 µg 
plasmid DNA was mixed with 3 µl transfection reagent and used to trans-
fect 150,000 cells. Cells were used 48 h after transfection. For nega-
tive  control  transfections,  a  nontargeting  shRNA  expression  plasmid 
was used (MISSION).
Cord formation assay
10,000 bEnd.3 endothelial cells were plated onto matrigel-coated 3-well 
chamber slides (BD) in the presence or absence of either 10,000 SPARC
+/+ 
or SPARC
/ pericytes and allowed to self-assemble into cords for 17 h in 
DME supplemented with 0.75% fetal bovine serum at 37°C before visual-
ization by fluorescent microscopy. Before use in the assays, bEnd.3 cells 
and pericytes were stained with either the red fluorochrome PKH26 or the 
green  fluorochrome  PKH67,  respectively  (Sigma-Aldrich).  Experiments 
were performed three times and in triplicate. Images were taken at a 4× 
magnification, with five images taken per well. The peripheral zone of 
matrigel was avoided during image acquisition so to avoid cord artifacts 
associated with changes in surface elevation. Cord lengths and widths 
were calculated using NIS-Elements software (Nikon). For cord width   
measurements, widths were taken halfway into the length of each cord.
Transwell assay
Transwell inserts with 8-µm pores were used for migration assays. Inserts 
were placed in 24-well tissue-culture plates for the duration of experiments. 
The bottom sides of the insert membranes were coated with 10 µl of 1-µg/µl 
fibronectin for 1 h at 37°C. Inserts were then used immediately for experi-
ments (Sigma-Aldrich). 7,000 or 5,000 primary pericytes or 10T1/2 cells 
were added into the insert reservoir in DME in a total volume of 125 µl, 
whereas DME containing 0.1% fetal bovine serum was added into the   
tissue-culture plate well. Experimental conditions were always added to 
both the top and bottom of the transwell. Cells were allowed to migrate to 
the fibronectin-coated side of the insert membrane for 6 h. Cells on the 
noncoated side of the insert membrane were removed. Cells that migrated 
to the underside of the membrane were fixed in formalin and manually 
counted. Experiments were performed in triplicate and repeated two or three 
times as indicated in the figure legends.
TGF- ELISA and TGF-1 response gene expression
A TGF-1 ELISA kit (TGF-1 EMAX Immunoassay G7591) that detects the 
active form of TGF-1 was purchased from Promega. Sample preparation for 
active  TGF-1  ELISA  was  performed  as  follows:  primary  pericytes  were 
seeded at 150,000 cells per well in 6-well tissue-culture plates and cultured 
in 0.75% fetal bovine serum–supplemented DME in triplicate. Cells did not 
exhibit any expansion and remained subconfluent and viable for the dura-
tion of the experiment. Conditioned media and cell lysates were collected at 
24, 48, 72, and 96 h after seeding. A mammalian protein extraction re-
agent (M-PER) cell lysis buffer supplement with protease inhibitor (Complete 
Mini) was used for lysate preparation (Roche). ELISA was performed accord-
ing to kit instructions. Active TGF-1 concentrations were calculated by inter-
polating values onto a standard curve generated with TGF-1 accompanying 1317 SPARC as a regulator of pericyte migration • Rivera and Brekken
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(EastCoast Bio), blocked, and incubated with recombinant endoglin or 
recombinant SPARC. Bound endoglin or SPARC was detected with anti-
endoglin  (MJ7/18)  or  anti-SPARC  (mAb  303)  antibodies  or  detected 
with horseradish peroxidase–conjugated secondary IgG. Assays were 
developed using tetramethylbenzidine reagent (Thermo Fisher Scientific). 
Samples  were  added  in  triplicate,  and  the  experiment  was  repeated 
three times.
Surface protein labeling
Primary pericytes were grown to 80% confluency and then switched to 
0.75% fetal bovine serum–supplemented DME. Cells were then labeled 
with a cell surface protein isolation kit (Sulfo-NHS-SS-Biotin; Thermo Fisher 
Scientific) according to the manufacturer’s instructions. 4–10-cm dishes per 
pericyte genotype were used per fractionation. Fractionations were per-
formed twice with identical results.
Image acquisition
Epifluorescent  images  were  taken  using  a  microscope  (Eclipse  E600; 
Nikon) and a camera (CoolSNAP HQ; Photometrics). Images were ac-
quired and analyzed using NIS-Elements software. For visualization of immuno-
fluorescently stained cells, images were thresholded so as to not include a 
signal caused by the nonspecific binding of the fluorophore-conjugated 
secondary antibody alone and analyzed as JPEG 2000 files. Confocal im-
ages were taken using either a TCS-SP5 confocal microscope (Leica) or an 
Eclipse TE2000E confocal microscope (Nikon). Leica images were taken 
using the Imaging Application for Confocal SP5 software (Leica). Images 
were saved as Leica Image Files (.LIF) and analyzed using ImageJ software 
(National  Institutes  of  Health).  Contrast  and  brightness  were  adjusted 
equally in all channels using Photoshop (CS3 Extended; Adobe). Nikon 
images were taken using a camera (CoolSNAP ES) and EZ-C1 3.8 soft-
ware (Photometrics). Images were saved in the native ICS/IDS format.   
Images were processed using NIS-Elements software. Channels were thres-
holded so as to not include autofluorescence from the assay medium (10% 
FBS in DME containing phenol red). Nikon epifluorescent and confocal ob-
jectives (plan fluorite) had the following numerical apertures: 10×, 0.3; 20×, 
0.5; 40×, 0.75; and 100×, 1.3 in oil. Leica confocal images were 
taken using a 63× objective with a 1.4 numerical aperture in oil. Fluo-
rescent staining was performed using cyanine (Cy3) or fluorescein iso-
thiocyanate–conjugated secondary antibodies (Jackson ImmunoResearch 
Laboratories, Inc.).
Statistics
Student’s  t  test  analysis  or  analysis  of  variance  was  performed  for  all 
experiments.
Online supplemental material
Fig. S1 shows vinculin and phalloidin staining used to assess focal adhe-
sion  formation  in  primary  pericytes.  Fig.  S2  shows  exogenous  SPARC 
blocked the anti-TGF-–induced enhancement of SPARC
/ pericyte migra-
tion. Fig. S3 shows that SPARC
/ pericytes exhibit enhanced basal TGF- 
activity.  Online  supplemental  material  is  available  at  http://www.jcb 
.org/cgi/content/full/jcb.201011143/DC1.
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